Wiley (WLY) Q4 2026 earnings review
A Margin Story, Not a Growth Story
Wiley closed FY26 with flat revenue ($1,677M, 0% at constant currency) as Research's 4% growth was cancelled out by a 7% drop in Learning. The real progress was below the top line: aggressive cost cuts pushed Adjusted EBITDA margin to a record 26.2% (+220bps) and lifted Adjusted EPS 15% to $4.19. Free Cash Flow jumped 55% to $195M. After the year closed, Wiley made its biggest acquisition since 2007, buying Emerald Publishing for $452M. FY27 guidance points to continued margin expansion (26.5-27.5%) and another step up in EPS ($4.60-$5.05), but organic revenue growth is still only low-to-mid single digits.
🐂 Bull Case
Three straight years of margin gains: Adjusted EBITDA margin went 22.8% -> 24.0% -> 26.2%, and FCF conversion reached 44% from 31% two years ago. Cost discipline is structural, not a one-off, with corporate expenses down 15% for the year.
AI revenue grew 23% to $49M, but the more important shift is recurring revenue scaling from ~$1M to ~$8M, guided to grow 2-3x again in FY27. Wiley now serves 19 corporate subscription customers, up from 10 a quarter earlier.
🐻 Bear Case
Organic revenue was flat for the year and is guided to only low-to-mid single digits in FY27. Learning fell 7%, and Research's 4% growth leans on AI licensing and open access rather than broad acceleration. Growth is being manufactured through cost cuts and an acquisition, not demand.
GAAP EPS of $4.16 (up 172%) and net income of $222M are heavily inflated by a $58M tax valuation allowance release. The effective tax rate was -3.0%. Adjusted EPS, which strips this out, grew a far more modest 15%.
⚖️ Verdict: ⚪
Neutral. This is a high-quality execution story (record margins, strong cash, disciplined capital returns) wrapped around a stagnant top line. The cost lever and Emerald can carry earnings for a year or two, but flat organic revenue and an AI base that is still small leave the long-term growth case unproven.
Key Themes
Learning in Structural Decline
Learning revenue fell 7% (CC) for the full year, with Professional down 10% and Academic down 5%. Management blames Amazon inventory practices, soft consumer/corporate spending, and lower AI licensing comps. Notably, management has called these 'great franchises but not growth franchises' and put the portfolio under review ('no sacred cows'). FY27 is expected to 'improve' but is not characterized as a growth engine. The high segment EBITDA margin (38.0%, +60bps) is being held up by cost cuts, not demand.
Cost Reduction Driving Record Margins
The earnings story is a cost story. Corporate (unallocated) expenses on an Adjusted EBITDA basis fell from $166M to $143M (-15%), and were down 22% (CC) in Q4 alone. Three workstreams drive it: tech transformation (the largest, including the Virtusa managed-services partnership and sale of the Sri Lanka center), shared-services consolidation, and AI productivity in legal, marketing, and content operations. Tech product-development spend is shifting from ~30-35% to 50-60% of the tech budget. This is what lifted Adjusted Operating Margin 260bps to 17.7%.
AI Recurring Revenue Beginning to Scale
Total AI revenue reached $49M (+23%), but the strategically important number is the recurring base climbing from ~$1M to ~$8M, guided to 2-3x again in FY27. The model is moving from lumpy LLM training deals (4 training customers) toward subscription knowledge feeds, now at 19 corporate customers (12 life sciences, 4 engineering/materials/chemistry, 2 financial, 1 ag/food), including 7 of the top 10 global pharma companies. The Nexus licensing service has 41 publisher partners and generated $19M in FY26. Lifetime AI revenue has surpassed $110M.
Emerald Acquisition: Buying Scale and a Recurring Stream
After year-end, Wiley acquired UK-based Emerald Publishing for $452M (GBP 337M) at ~7x synergized Adjusted EBITDA, its largest deal since 2007. Emerald adds ~$85M of revenue (92% recurring, 99.6% retention, 37-38% EBITDA margin), 485 journals, and category leadership in economics, business, and finance, expanding Wiley's portfolio to ~2,500 journals. The all-cash deal targets $30M of cost synergies by year 3. Critically, only 15% of Emerald's revenue comes from North America versus 40% of global social-sciences spend, framing a cross-sell opportunity. Management expects ~$0.10 EPS accretion in FY27 but $15M of FCF dilution in year 1.
Research Share Gains and Output Growth
Research grew 4% (CC) for the year on strong leading indicators: full-year submissions up 25% and output up 11%, both well above the 6-8% industry rate, supporting future recurring subscription and open-access revenue. The Advanced journal portfolio (25+ journals) reached ~$70M in revenue at strong double-digit growth. The ResearchXchange platform landed its first external publisher client (Liverpool University Press), opening a new path to monetize and reduce cost-to-publish. New society wins include ASME and a 30th-year renewal with the American Cancer Society.
Flat Revenue Behind the Record-Margin Headlines
A specific data point cuts against the 'breakout year' narrative: adjusted revenue was flat at constant currency for the full year, and reported revenue actually declined 0.1% YoY ($1,676.5M vs $1,677.6M). Q4 revenue was also flat (CC). Every headline that management leads with (record margins, +55% FCF, +15% EPS) is derived from cost reduction, tax effects, and lower capex rather than top-line demand. The growth re-acceleration management projects depends on AI scaling and Emerald, both still early.
Research Solutions Pivoting Away From Legacy Advertising
Research Solutions (recruitment and advertising) declined 4% (CC) in Q4 on a soft recruitment market. Management is shifting this business from legacy advertising to an audience-analytics platform built on modern ad-tech, AI-driven product innovation, and verified audiences, positioning it as the third AI growth vector (audience monetization). This is an early-stage transition tied to a currently shrinking revenue line.
Late Renewal Signings Shifted Cash Into Q1
Free cash flow of $195M, while up 55%, was moderated by larger journal renewals closing late in the fiscal year, pushing related cash collection from Q4 into Q1 FY27. Management characterizes this as timing endemic to this cycle rather than a trend, and says it will be recaptured. Worth monitoring, since it temporarily flatters FY27's opening quarter and means the reported FY26 FCF understates underlying collection.
Other KPIs
GAAP net income tripled to $222M and GAAP EPS rose 172% to $4.16, but these figures are not what they appear. The company recorded a tax benefit of $6.5M (a -3.0% effective rate) versus a $59M provision the prior year, driven by a $58.3M valuation allowance release. In Q4 alone the valuation allowance contributed a $58.0M benefit. This is a non-cash, non-recurring item. Adjusted EPS, which removes it, grew a more representative 15% to $4.19.
FCF (less product development spending) rose from $126M to $195M, with conversion stepping up from 32% to 44%. The gain came from higher cash earnings and lower capex (combined capex + product development fell to $65M from $77M). FY27 guidance of $205M implies only ~5% growth because capex normalizes back up to $80M and Emerald is dilutive by $15M in year one. Cash returned to shareholders hit a record $174M, including $100M of buybacks (+67%) at an average price of $35/share; the dividend was raised for the 32nd consecutive year.
Leverage improved to 1.4x from 1.8x, with net debt falling to $608M from $714M, aided by ~$120M of divestiture proceeds. Following the June 1 Emerald close (including expected synergies), pro forma leverage rose to 2.1x, still inside the 1.5x-2.5x comfort range. Wiley also expanded its credit facility by $300M to $1.6B of total capacity, preserving flexibility for continued buybacks and further portfolio moves.
Guidance
Accelerating. The midpoint of $4.82 implies ~15% growth from FY26's $4.19, in line with FY26's growth pace, with the range spanning +10% to +21%. Emerald contributes only ~$0.10, so the bulk is organic operating leverage. Growth is driven by higher Adjusted Operating Income, partially moderated by a higher tax rate.
Accelerating, but at a slowing pace. The midpoint of 27.0% adds 30-130bps over FY26's 26.2%, versus the 220bps gain delivered in FY26. The narrower step reflects that the largest, easiest corporate cost cuts have already been taken; further expansion depends on tech transformation, AI productivity, and Emerald synergies that ramp mainly in FY28-29.
Stable. Using a ~3% midpoint, this is roughly flat-to-modestly-better than FY26's 0% organic. The guidance excludes ~$78M of Emerald revenue (11 months), which adds ~4.7% of inorganic growth on the FY26 base. The improvement story rests on Research holding mid-single-digit growth and Learning moving from -7% toward stabilization, plus another strong AI year.
Decelerating sharply. After +55% in FY26, FCF is guided up only ~5% to $205M. The drag is mechanical: capex normalizes to $80M (from $65M), Emerald is dilutive by $15M in year one, plus expected restructuring costs and higher cash taxes. Underlying cash earnings still grow, but the headline FCF growth rate collapses versus FY26.
Key Questions
What Is Sustainable Organic Growth?
Three years of record margin gains have masked flat organic revenue. Once the cost-cut and Emerald tailwinds are fully captured, what is the durable organic growth rate of the combined business, and at what point does the top line need to carry the earnings story?
Learning: Fix or Divest?
Management has called Learning 'not a growth franchise' and said there are 'no sacred cows.' With Professional down 10% for the year, what specific criteria would trigger a divestiture, and what is the realistic timeline for the promised FY27 improvement versus another year of decline?
AI Recurring Revenue Path Beyond FY27
Recurring AI revenue is guided to 2-3x off an $8M base. Beyond the FY27 step, what is the medium-term scale of the three growth vectors (database solutions, applied research intelligence, audience monetization), and what conversion rates from the 38K Gateway trial users and 19 corporate customers underpin it?
Tax Rate Normalization
FY26 GAAP results were materially flattered by a $58M valuation allowance release. What is the expected normalized cash and effective tax rate going forward, and how much does the 'higher tax rate' cited in FY27 guidance weigh on EPS?
Emerald Synergy Realization Risk
The $452M Emerald deal hinges on $30M of cost synergies, largely in years 2-3. What are the integration milestones and key execution risks for migrating 485 journals and 8,000 books onto Wiley's platform, and what cross-sell revenue is actually underwritten in the deal returns?